Capital Surge Fuels Brain-Computer Interface Boom: Major Funding Rounds and Product Advances in Early 2026

　　【Pharmaceutical Network Industry DynamicsIn recent years, the brain-computer interface market has been growing increasingly popular. According to data, in 2025, there were 26 financing events in the brain-computer interface field, with a total financing amount reaching 1.778 billion yuan. Among these, more than 6 financing events exceeded 100 million yuan each. And since this year, due to various favorable factors, the heat in the brain-computer interface market has not diminished. Incomplete statistics show that in just over two months since the beginning of the year, there have been 10 financings completed in China's brain-computer interface sector, with generally large financing amounts.
 

On January 7, BrainCo completed approximately 2 billion yuan in financing. It has been deeply engaged in non-invasive brain-computer interface technology for nearly a decade and has successively launched various brain-computer interface-related products, such as intelligent bionic hands, intelligent bionic legs, and brain-computer intelligent sleep devices, building a presence across medical rehabilitation, consumer health, and cutting-edge fields.RobotProduct matrix. The funds from this substantial financing will be used to accelerate technological iteration, expand into global markets, and further enhance the product matrix in areas such as rehabilitation, health and wellness, and human-computer interaction.
 

Arfysica Innovation Completed B+ and C Rounds of Financing in January and February, with Both Rounds Reaching Hundreds of Millions of Yuan. The B+ round was led by the National SME Development Fund and Oriental Fortune Investment, while the C round was jointly "bid" by multiple institutions including Daohe Capital, Oriental Hengxin, and Xinding Capital. Arfysica Innovation is a leading company in the non-invasive brain-computer interface sector, with a product portfolio deeply covering three major areas: limb motor dysfunction caused by central nervous system injury, consciousness and cognitive disorders, and neurodevelopmental disorders. Multiple rounds of financing will help the company continuously drive generational leaps in brain-computer interface technology, deepen diverse industrial applications, and build an innovative full-chain ecosystem for brain-computer interfaces across various scenarios.
 

BCIFlex Announces Completion of RMB 300 Million Series A+ Financing in February. The funds raised in this round will be primarily used to advance large-scale clinical trials and the iteration of high-throughput flexible brain-computer interface products, accelerating the technology's transition to clinical applications. This marks the second major financing round secured by the company within half a year, following its over RMB 300 million Series A financing in August 2025. The consecutive capital endorsements in a short period fully attest to the market's dual recognition of BCIFlex's technical strength and development potential in the invasive brain-computer interface sector.
 

Casibrain Technology Announces Completion of Tens of Millions of Yuan in B-Round Financing in MarchAs a medical device enterprise incubated by the Institute of Automation, Chinese Academy of Sciences, which integrates research and development, production, and sales, Casibrain Technology is committed to the production, registration, and sales of medical devices that transform cutting-edge brain science technologies from the Institute of Automation, Chinese Academy of Sciences. This round of financing will fully support its efforts to deepen the industrial chain layout of brain-computer interfaces, and accelerate the clinical transformation and industrial implementation of advanced technologies.
 

Currently, brain-computer interfaces have been explicitly included in China’s “15th Five-Year Plan” as a key future industry for development, becoming an important direction for fostering new productive forces and promoting technological self-reliance. Industry insiders believe that, with favorable policies and continued high investment enthusiasm, core technology breakthroughs, clinical translation, regulatory and ethical alignment, and commercialization pathway exploration in the brain-computer interface field will all see accelerated progress. This sector is now entering a critical phase of accelerated clinical implementation and commercialization.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.